The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Clinicopathologic features and treatment outcomes of patients (pts) with HER2-positive (pos) adenocarcinomas (ACA) of the esophagus (E) and gastroesophageal junction (GEJ).
B. E. Phillips
No relevant relationships to disclose
R. R. Tubbs
No relevant relationships to disclose
T. W. Rice
No relevant relationships to disclose
L. A. Rybicki
No relevant relationships to disclose
T. Plesec
No relevant relationships to disclose
C. P. Rodriguez
No relevant relationships to disclose
G. M. Videtic
No relevant relationships to disclose
J. P. Saxton
No relevant relationships to disclose
D. I. Ives
No relevant relationships to disclose
D. J. Adelstein
Research Funding - AstraZeneca; Sanofi